SurpassMD vs Remedy Meds: GLP-1 Pricing Gap Explained
Advertising disclosure: SurpassMD is an advertising partner of Peptide Dossier. Pricing and program facts below were verified in July 2026 and apply to both platforms equally.
SurpassMD and Remedy Meds sit at opposite ends of compounded GLP-1 pricing: $134 versus $299 per month for semaglutide, $199 versus $399 for tirzepatide — the widest gap among major platforms as of July 2026. Both bill month-to-month with no prepay tiers, so the comparison comes down to what Remedy Meds' unlimited provider access is worth to you.
Side-by-Side Comparison (July 2026)
| Feature | SurpassMD | Remedy Meds |
|---|---|---|
| Semaglutide | From $134/mo | $299/mo |
| Tirzepatide | From $199/mo | $399/mo |
| Oral option | Oral semaglutide | None |
| Brand-name option | None | Ozempic $1,299, Zepbound $1,399 |
| Provider access | Async review + support | Unlimited video + messaging |
| Billing | Month-to-month | Month-to-month |
| Shipping | Cold, within 48 hours | 3-7 business days |
| Regulatory history | New brand (2026), no actions | FDA warning letter Sept 2025 (marketing) |
| Coverage | 50 states + DC | Most states |
Verdict: Which Should You Choose?
SurpassMD wins on price, shipping speed, and the oral semaglutide option, with identical billing flexibility. Remedy Meds earns its premium only for patients who will genuinely use unlimited provider access or want brand-name medication on the same platform. The September 2025 FDA warning letter is worth weighing when evaluating how each platform communicates about compounded medication risk.
Full reviews: SurpassMD review and Remedy Meds review. See the ranked best GLP-1 telehealth providers and the full price comparison.
Frequently Asked Questions
At advertised entry prices as of July 2026: $165/month cheaper for compounded semaglutide ($134 vs $299) and $200/month cheaper for compounded tirzepatide ($199 vs $399). Over a 12-month course at entry rates, that is roughly $1,980-2,400. Both platforms' actual prices depend on the dose prescribed, and neither offers prepay discounts on these rates — SurpassMD because its floor is already low, Remedy Meds because it only bills month-to-month.
Unlimited video calls and messaging with the care team between monthly check-ins — genuinely unusual in the category, where most platforms cap provider contact. Remedy Meds also offers brand-name Ozempic ($1,299) and Zepbound ($1,399), which SurpassMD does not. For patients who expect heavy side-effect management or frequent titration questions, unlimited access has real value.
Yes. In September 2025 the FDA cited Remedy Meds for misbranding: marketing that implied its compounded semaglutide and tirzepatide were FDA-approved equivalents of brand-name drugs. The letter concerned advertising claims, not product safety findings, and the company continues to operate. It is still a relevant signal about marketing practices when comparing platforms.
Yes, both are month-to-month, cancel-anytime models with no prepaid tiers required. This makes the entry-price comparison unusually clean: there is no prepay discount at either platform muddying the math, unlike TrimRx or Fridays where committed rates change the picture.
SurpassMD advertises cold-chain shipping within 48 hours of provider approval; Remedy Meds quotes 3-7 business days. Both ship compounded injectables cold-packed with tracking, and both include shipping in the monthly price.
On price, SurpassMD wins this matchup at every point of comparison, and both share the same month-to-month billing structure. Remedy Meds makes sense for patients who specifically want unlimited provider access or a brand-name option on the same platform, and who will pay $165-200/month more for it. If you rarely message your provider, that premium buys nothing.
This page is informational and is not medical advice. SurpassMD is an advertising partner of Peptide Dossier. Compounded medications are not FDA-approved or reviewed for safety, effectiveness, or quality. Prescriptions are never guaranteed. Pricing verified July 2026 and subject to change.